Skip Navigation LinksHome > February 2014 - Volume 9 - Issue 2 > Incorporating Immune-Checkpoint Inhibitors into Systemic The...
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0000000000000074
State of the Art: Concise Review

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC

Champiat, Stéphane MD*; Ileana, Ecaterina MD; Giaccone, Giuseppe MD, PhD; Besse, Benjamin MD, PhD§; Mountzios, Giannis MD, PhD; Eggermont, Alexander MD, PhD; Soria, Jean-Charles MD, PhD

Collapse Box

Abstract

Despite current therapeutic options metastatic non– small-cell lung cancer (NSCLC) remains incurable. Targeted therapies have opened new opportunities for several molecular subtypes, but virtually all patients treated will ultimately develop progressive disease by treatment resistance. Recent clinical trials have shown that immune-checkpoint blockade can result in striking and durable responses in metastatic NSCLC. These impressive results are yet to be confirmed in following trials; nonetheless, NSCLC therapeutic strategies will most likely need to integrate immune-checkpoint inhibitors in the near future. Interestingly, conventional therapies are capable of modulating the immune system and can therefore interact directly or indirectly with immunotherapies. This suggests that some combinations might have synergistic activity and lead to improved efficacy. Conventional and targeted therapies can induce rapid tumor lysis, and immune-checkpoint blockade can then help to induce a sustained immune-mediated tumor control. Moreover, the distinctive toxicity profile associated with immune-checkpoint modulators makes them good candidates for combination strategies. Here we summarize the results of immune-checkpoints trials in NSCLC, and also report how current therapeutic options can modulate the immune system. We provide a rationale and identify potential challenges for immune-checkpoint blockade combinations with conventional therapeutics in NSCLC.

Copyright © 2013 by the International Association for the Study of Lung Cancer

Login

Article Tools

Share

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.